When Science magazine published its annual breakthrough of the year issue last week, one of the contenders for the top scientific advance of the year – an honor that went to the discovery of the Higgs boson – was a new genome editing technique, transcription activator-like effector nucleases or TALENs.
It's the time of year to make lists and check them twice. Science published its Breakthrough of the Year issue describing its picks for the most important scientific advances of the year on Friday.
It's a cell-eat-cell world in there. And apparently, that's a good thing, too. "In the body, almost any cell can eat other cells," Kodi Ravichandran told BioWorld International. "Especially their neighbors who are dying."
It's a cell-eat-cell world in there. And apparently, that's a good thing, too. "In the body, almost any cell can eat other cells," Kodi Ravichandran told BioWorld Today. "Especially their neighbors who are dying."
ATLANTA – Nineteen years to the day after the activation of the JAK/STAT pathway by interferon was first described in the Dec. 9, 1993, issue of Nature, scientists at Incyte Corp. described the pathway from that description to the first approved inhibitor of the JAK/STAT pathway, Jakafi (ruxolitinib, Incyte Corp) at the American Society of Hematology (ASH) annual meeting last week.
Michele de Luca, of the University of Modena's Center for Regenerative Medicine, introduced himself in an unusual fashion for a plenary speaker at a hematology convention. "I have nothing to do with blood," he told his audience at Tuesday's Presidential Symposium on stem cells at the American Society of Hematology's (ASH) annual meeting.
ATLANTA – The American Society of Hematology's (ASH) annual meeting embraces, more than many other conferences, both the basic research and the clinical treatment side of diseases their members focus on.
Triple-negative breast cancer (TNBC) is named for what it does not have. This subtype of breast cancer does not express estrogen receptors, the progesterone receptor, or HER2/neu. That classification, though, doesn't give doctors any clues as to what might actually work to fight it – only what won't.
The relationship between cancer, cancer treatments, inflammation and immunity had another layer of complexity added to it with the report this week that chemotherapy can contribute to promoting tumor growth via activating the inflammasome in some types of immune system cells, which ultimately led to angiogenesis.
